Severe COVID-19
Indication: Hospitalized patients with Severe COVID-19
Title: Phase 2 Randomized Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor in Patients with Severe COVID-19
Drug: Selinexor
This study has been discontinued as of August 2020
Please visit clinicaltrials.gov for more information about this study
| Phase 1 | Phase 2 | Phase 3 | Commercial |
|---|---|---|---|
|
Phase 1
|
Phase 2
|
Phase 3
|
Commercial
|